Cargando…
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Adeno-associated viruses (AAV) have emerged as the lead vector in clinical trials and form the basis for several approved gene therapies for human diseases, mainly owing to their ability to sustain robust and long-term in vivo transgene expression, their amenability to genetic engineering of cargo a...
Autores principales: | Rapti, Kleopatra, Grimm, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586419/ https://www.ncbi.nlm.nih.gov/pubmed/34777364 http://dx.doi.org/10.3389/fimmu.2021.753467 |
Ejemplares similares
-
Induction of Hepatitis E Virus Anti-ORF3 Antibodies from Systemic Administration of a Muscle-Specific Adeno-Associated Virus (AAV) Vector
por: Maurer, Lars, et al.
Publicado: (2022) -
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
por: Ronzitti, Giuseppe, et al.
Publicado: (2020) -
Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
por: Basner-Tschakarjan, Etiena, et al.
Publicado: (2014) -
Adeno-Associated Virus (AAV) Versus Immune Response
por: Rabinowitz, Joseph, et al.
Publicado: (2019) -
Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood
por: Smith, Corinne J., et al.
Publicado: (2022)